These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 19495748)

  • 1. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
    Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
    Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
    Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
    Strobel K; Dummer R; Steinert HC; Conzett KB; Schad K; Lago MP; Soyka JD; Veit-Haibach P; Seifert B; Kalff V
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1786-95. PubMed ID: 18458901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.
    Strobel K; Skalsky J; Steinert HC; Dummer R; Hany TF; Bhure U; Seifert B; Pérez Lago M; Joller-Jemelka H; Kalff V
    Dermatology; 2007; 215(3):192-201. PubMed ID: 17823514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.
    Strobel K; Skalsky J; Kalff V; Baumann K; Seifert B; Joller-Jemelka H; Dummer R; Steinert HC
    Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1366-75. PubMed ID: 17390135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
    Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
    Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
    Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
    Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
    Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
    Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
    Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
    Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-100B concentrations predict disease-free survival in stage III melanoma patients.
    Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
    Servois V; Mariani P; Malhaire C; Petras S; Piperno-Neumann S; Plancher C; Levy-Gabriel C; Lumbroso-le Rouic L; Desjardins L; Salmon RJ
    Eur J Surg Oncol; 2010 Feb; 36(2):189-94. PubMed ID: 19775851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
    Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
    J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography.
    Francken AB; Fulham MJ; Millward MJ; Thompson JF
    Eur J Surg Oncol; 2006 Sep; 32(7):780-4. PubMed ID: 16765562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients.
    Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP
    Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma.
    Peric B; Zagar I; Novakovic S; Zgajnar J; Hocevar M
    BMC Cancer; 2011 Aug; 11():328. PubMed ID: 21810220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of serum S-100B in malignant melanoma.
    Andrés R; Mayordomo JI; Zaballos P; Rodino J; Isla D; Escudero P; Elosegui L; Filipovich E; Saenz A; Polo E; Tres A
    Tumori; 2004; 90(6):607-10. PubMed ID: 15762365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.